Lab device developer Unchained Labs has announced its acquisition of Belgian company Trinean. Trinean made waves in the lab devices sector with its DropSense system, which measures protein, DNA and RNA concentration in minute biologics and genomics samples. The transaction makes for Unchained Labs’ 5th acquisition in just over 2 years.

DropSense96 is the only system on the market that can measure up to 96 high concentration protein samples in 5 minutes. Scientists simply load 2 microliters of sample into the proprietary DropPlate and enter it into the system. DropSense systems are a completely worry-free way to measure concentrations — no need to dilute or mix samples, clean anything before or after a run, or calibrate the system.

Philippe Stas, CEO of Trinean, comments:
“Since we started 10 years ago, Trinean has made micro-volume concentration measurements higher throughput and more accessible to life science researchers. Unchained Labs is the ideal home for DropSense and this acquisition is great for our customers, partners and employees.”

Tim Harkness, Founder and CEO of Unchained Labs says:
“These products are a perfect strategic fit for Unchained Labs. Concentration measurement is central to everything our customers do and DropSense96 is the only product in the world that does it for biologics at high concentration with high-throughput.”

In just over 2 years, Unchained Labs has grown to over 130 employees, $35M+ in revenue, 8 product lines and has direct distribution around the world. In connection with this transaction, the company raised $13M in a Series C financing. The original syndicate partners, Novo Ventures, Canaan Partners and TPG Biotech all participated in the financing.